相似文献
1
Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States.
Blood. 2024 May 30;143(22):2332-2335. doi: 10.1182/blood.2024024209.
2
Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Wien Klin Wochenschr. 1999 Mar 12;111(5):181-91.
3
Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
Blood. 2022 Jul 14;140(2):89-98. doi: 10.1182/blood.2021014810.
4
Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Haemophilia. 1998;4 Suppl 3:53-62. doi: 10.1046/j.1365-2516.1998.0040s3053.x.
5
In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.
Blood. 1997 Nov 1;90(9):3555-67.
6
An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
Expert Rev Hematol. 2023 Mar;16(3):157-161. doi: 10.1080/17474086.2023.2184339. Epub 2023 Mar 2.
7
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial.
Eur J Haematol. 2023 Jul;111(1):29-40. doi: 10.1111/ejh.13949. Epub 2023 Apr 11.
8
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Blood. 2013 Aug 1;122(5):648-57. doi: 10.1182/blood-2013-01-479527. Epub 2013 Jun 18.
9
In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma-derived von Willebrand factor products.
Haemophilia. 2024 Jan;30(1):151-160. doi: 10.1111/hae.14892. Epub 2023 Nov 5.
10
Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.
J Blood Med. 2023 Jun 13;14:399-411. doi: 10.2147/JBM.S395845. eCollection 2023.
引用本文的文献
1
Prophylaxis in von Willebrand disease with von Willebrand factor concentrate and nonfactor therapies.
Res Pract Thromb Haemost. 2024 Oct 28;8(8):102599. doi: 10.1016/j.rpth.2024.102599. eCollection 2024 Nov.
本文引用的文献
1
Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.
J Blood Med. 2023 Jun 13;14:399-411. doi: 10.2147/JBM.S395845. eCollection 2023.
2
Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
Blood. 2022 Jul 14;140(2):89-98. doi: 10.1182/blood.2021014810.
3
Prophylactic management of patients with von Willebrand disease.
Ther Adv Hematol. 2021 Dec 22;12:20406207211064064. doi: 10.1177/20406207211064064. eCollection 2021.
4
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.
Blood Adv. 2021 Jan 12;5(1):301-325. doi: 10.1182/bloodadvances.2020003264.
5
Translating the success of prophylaxis in haemophilia to von Willebrand disease.
Thromb Res. 2021 Mar;199:67-74. doi: 10.1016/j.thromres.2020.12.030. Epub 2021 Jan 6.
6
Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.
Pharmacoeconomics. 2020 Oct;38(10):1135-1145. doi: 10.1007/s40273-020-00942-2.
7
Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease.
Haemophilia. 2020 Mar;26(2):e44-e48. doi: 10.1111/hae.13916. Epub 2019 Dec 22.
8
Von Willebrand disease in the United States: perspective from the Zimmerman program.
Ann Blood. 2018 Jan;3. doi: 10.21037/aob.2017.12.05. Epub 2018 Jan 26.
9
Gene therapy in hemophilia A: a cost-effectiveness analysis.
Blood Adv. 2018 Jul 24;2(14):1792-1798. doi: 10.1182/bloodadvances.2018021345.
10
Von Willebrand's Disease.
N Engl J Med. 2016 Nov 24;375(21):2067-2080. doi: 10.1056/NEJMra1601561.
Zotero 插件